KMT2A and acute myeloid leukemia: AML Patients with MLL-rearrangement generally have poor prognoses and often suffer from early relapse after treatment with current standard induction therapies, a 7-day continuous infusion of cytarabine at the dosage of 100 or 200 mg/m2per day on days 1 to 7 and daunorubicin at 60 mg/m2 per day on days 1 to 3 [12, 13].